Please Note: This trial is no longer enrolling new participants
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
| Protocol No. | PHO-COG-FALLON-AALL1131 | Scope | National |
|---|---|---|---|
| Principal Investigator | Sandeep Batra | Treatment Type | Treatment |
| Age Group | Children | Phase | Phase III |
